Gilead Sciences, Inc. $GILD Shares Acquired by Principal Financial Group Inc.

Principal Financial Group Inc. raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 27.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,762,006 shares of the biopharmaceutical company’s stock after purchasing an additional 379,592 shares during the quarter. Principal Financial Group Inc.’s holdings in Gilead Sciences were worth $216,269,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in GILD. Corundum Trust Company INC acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at $26,000. Ares Financial Consulting LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $28,000. Financial Consulate Inc. increased its position in shares of Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 109 shares during the period. North Star Investment Management Corp. increased its position in shares of Gilead Sciences by 54.8% in the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 86 shares during the period. Finally, MTM Investment Management LLC increased its holdings in Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 176 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: AHF says Gilead’s EPS could rise ~52% because state AIDS drug program shortfalls have increased reliance on commercial/retail supply, implying near-term revenue upside for Gilead’s HIV portfolio. Gilead’s Earnings Skyrocket as Florida’s AIDS Drug Program Falters, says AHF
• Positive Sentiment: Brokerage commentary and price-target coverage are constructive — a recent note cites a $157.35 target, supporting investor expectations of upside versus current levels. Brokerages Set Gilead Sciences, Inc. (NASDAQ:GILD) Price Target at $157.35
• Neutral Sentiment: Use of Yeztugo (twice-yearly HIV-prevention shot) is rising since launch, which supports Gilead’s growth story in prevention, but adoption is still early and incremental to overall revenues. Focus: Use of Gilead’s HIV prevention shot rises, but US insurance gaps remain
• Neutral Sentiment: Analyst/estimate deep dives (Zacks/market write-ups) are circulating ahead of quarterly reporting; these pieces highlight key metrics investors will watch (sales mix of HIV products, hepatitis/oncology performance, and guidance). That keeps focus on fundamentals rather than a single headline. Curious about Gilead (GILD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
• Neutral Sentiment: Brand/marketing recognition (PLAN C Impact 50) is positive for awareness but unlikely to move near-term fundamentals materially. Eight PLAN C Client Brands Named to the 3AF 2026 Impact 50
• Negative Sentiment: Insurance coverage gaps for Yeztugo remain a real constraint — patients who want the injection can face reimbursement hurdles, which could cap upside in medium-term prevention revenue if not resolved. Use of Gilead’s HIV prevention shot rises, but US insurance gaps remain

Insider Activity

In other news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the sale, the insider directly owned 128,779 shares in the company, valued at $18,152,687.84. This trade represents a 2.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the sale, the chief executive officer owned 632,567 shares in the company, valued at $81,702,353.72. This trade represents a 1.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 178,640 shares of company stock worth $26,584,250 in the last ninety days. Company insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on GILD shares. Rothschild & Co Redburn increased their price target on shares of Gilead Sciences from $159.00 to $170.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. UBS Group increased their price target on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, January 26th. BMO Capital Markets increased their price target on shares of Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday, January 26th. TD Cowen increased their price target on Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Finally, Royal Bank Of Canada increased their price target on Gilead Sciences from $118.00 to $123.00 and gave the stock a “sector perform” rating in a research report on Tuesday, April 7th. Twenty-four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $157.35.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $133.48 on Wednesday. The stock has a market capitalization of $165.68 billion, a price-to-earnings ratio of 19.72, a PEG ratio of 1.75 and a beta of 0.31. Gilead Sciences, Inc. has a 12 month low of $95.29 and a 12 month high of $157.29. The firm’s 50 day simple moving average is $140.14 and its 200-day simple moving average is $132.66. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business’s revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the company earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts expect that Gilead Sciences, Inc. will post 8.62 EPS for the current year.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.